title: Nonspecific, reversible inhibition of voltage-gated calcium channels by CaMKII inhibitor CK59.
abstract: Investigation of kinase-related processes often uses pharmacological inhibition to reveal pathways in which kinases are involved. However, one concern about using such kinase inhibitors is their potential lack of specificity. Here, we report that the calcium-calmodulin-dependent kinase II (CaMKII) inhibitor CK59 inhibited multiple voltage-gated calcium channels, including the L-type channel during depolarization in a dose-dependent manner. The use of another CaMKII inhibitor, cell-permeable autocamtide-2 related inhibitory peptide II (Ant-AIP-II), failed to similarly decrease calcium current or entry in hippocampal cultures, as shown by ratiometric calcium imaging and whole-cell patch clamp electrophysiology. Notably, inhibition due to CK59 was reversible; washout of the drug brought calcium levels back to control values upon depolarization. Furthermore, the IC50 for CK59 was approximately 50 μM, which is only fivefold larger than the reported IC50 values for CaMKII inhibition. Similar nonspecific actions of other CaMKII inhibitors KN93 and KN62 have previously been reported. In the case of all three kinase inhibitors, the IC50 for calcium current inhibition falls near that of CaMKII inhibition. Our findings demonstrate that CK59 attenuates activity of voltage-gated calcium channels, and thus provide more evidence for caution when relying on pharmacological inhibition to examine kinase-dependent phenomena.
authors: Department of Biological Sciences, Marquette University, Milwaukee, WI 53201, USA. andrew.karls@marquette.edu
authors: Andrew S
authors: AS
authors: Karls
authors: Michelle
authors: M
authors: Mynlieff
mesh_terms: D000818:Animals; D002118:Calcium / Q000378:metabolism; D015220:Calcium Channels / Q000378:metabolism*; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015640:Ion Channel Gating / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D015220:Calcium Channels; D047428:Protein Kinase Inhibitors; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D002118:Calcium
references: Neurochem Int. 2001 Nov-Dec;39(5-6):459-68
references: 11578781
references: J Biol Chem. 2004 May 28;279(22):23813-21
references: 15044483
references: J Biol Chem. 2004 Mar 26;279(13):12484-94
references: 14722083
references: Neuropharmacology. 1995 Jul;34(7):731-41
references: 8532140
references: Biochem Biophys Res Commun. 2006 Jul 14;345(4):1606-10
references: 16730662
references: J Neurosci Methods. 1997 Apr 25;73(1):35-44
references: 9130676
references: Cell Calcium. 2011 Jul;50(1):1-8
references: 21529938
references: Biochem Biophys Res Commun. 1995 Jul 26;212(3):806-12
references: 7626114
references: Cold Spring Harb Perspect Biol. 2011 Aug 01;3(8):a003947
references: 21746798
references: Endocrinology. 2007 Jan;148(1):374-85
references: 17008397
references: Biochem Biophys Res Commun. 1991 Dec 31;181(3):968-75
references: 1662507
references: J Physiol. 2006 Dec 1;577(Pt 2):513-23
references: 17008378
references: FEBS J. 2006 Feb;273(4):682-94
references: 16441656
references: J Physiol Sci. 2009 Jul;59(4):283-90
references: 19340532
references: Biochemistry. 1996 Jul 23;35(29):9400-6
references: 8755718
references: J Mol Cell Cardiol. 2010 Apr;48(4):773-80
references: 19883656
references: Pharmacol Rev. 2005 Dec;57(4):411-25
references: 16382099
references: J Neurosci Res. 2004 May 1;76(3):323-33
references: 15079861
references: Neuroscience. 2011 Apr 14;179:62-72
references: 21277353
references: J Biol Chem. 1985 Mar 25;260(6):3440-50
references: 3838314
references: Curr Opin Neurobiol. 2002 Jun;12(3):293-9
references: 12049936
references: Brain Res. 2006 May 23;1090(1):76-88
references: 16674933
references: Mol Pharmacol. 2004 Sep;66(3):761-9
references: 15322269
references: Dev Neurobiol. 2009 Nov;69(13):885-96; erratum 897-912
references: 19777558